Linagliptin is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor which suppresses the rapid degradation of endogenous glucagon-like peptide-1 (GLP-1). In clinical practice, it is used as an antidiabetic drug, but recent studies have confirmed its role in the activity of the central nervous system (CNS). The reported study focused on the role of linagliptin (10 and 20 mg/kg, ip) in the morphine rewarding effect, analyzing how the agent had influenced the conditioned place preference (CPP) in rats via the expression, acquisition, extinction and reinstatement of the morphine rewarding effect. The obtained results clearly demonstrated linagliptin to inhibit the expression and acquisition, to accelerate the extinction and, eventually, to reduce the reinstatement of morphine-induced CPP. The undertaken experiments significantly extended our knowledge on the mechanisms behind the morphine rewarding effect.

中文翻译：

---

利格列汀（一种选择性的二肽基肽酶4抑制剂）在大鼠吗啡奖励作用中的作用。

利格列汀是一种选择性的二肽基肽酶4（DPP-4）抑制剂，可抑制内源性胰高血糖素样肽1（GLP-1）的快速降解。在临床实践中，它被用作抗糖尿病药，但是最近的研究证实了它在中枢神经系统（CNS）活动中的作用。报道的研究集中于利格列汀（10和20 mg / kg，腹腔注射）在吗啡奖励作用中的作用，分析了该药物如何通过表达，获得，消光和还原而影响大鼠的条件性位置偏爱（CPP）。吗啡的奖励作用。获得的结果清楚地表明了利拉列汀抑制表达和获得，加速灭绝，并最终减少吗啡诱导的CPP的恢复。